



January 14, 2025

To Whom It May Concern

Company:	KYORIN Pharmaceutical Co., Ltd.
Representative:	Yutaka Ogihara Representative Director, President and CEO (Security Code: 4569, TSE Prime.)
Contact:	Yoshinori Tanifuji Director, Corporate Planning
Telephone:	03-6374-9702

KYORIN and BIODOL Enter Into Option Agreement for Novel Pain Treatment

KYORIN Pharmaceutical Co., Ltd. announced today that it has entered into an option agreement with BIODOL Therapeutics (Montarnaud France, CEO: Fabien Granier) for BDT272, a novel pain treatment candidate discovered by BIODOL.

Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize BDT272 in Japan and other territories in Asia (excluding China), and will pay an option fee to BIODOL. Upon exercising the option, KYORIN will enter into a license agreement with BIODOL, and will pay an upfront payment, milestone payments tied to the progress of developing and commercializing BDT272, and royalties based on net sales following its launch.

BDT272 is anticipated to demonstrate effective analgesic properties through the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of chronic pain condition such as neuropathic pain.

KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain as one of our key strategic therapeutic area for research and development. We anticipate that this innovative pain treatment candidate will provide a new treatment option for patients suffering from pain condition.

The impact on business performance for the fiscal year ending March 2025 is to be negligible.

[Reference]

About BIODOL Therapeutics

BIODOL Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). BIODOL Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various types of pain. The company holds exclusive rights to a portfolio of four patents and has received support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre.